The correlation between DLL3 and NKX2-1 in glioblastoma is notable as rovalpituzumab tesirine is indicated for glioblastoma in an ongoing basket trial (NCT 02709889) and requires DLL3 expression for enrollment. Here, DLL3 is linked to glioblastoma.